Jan 27 (Reuters) - The U.S. Centers for Medicare &

Medicaid Services ‌on Tuesday named the 15 new ​drugs targeted for

Medicare price negotiations ‍for 2028 including Pfizer ( PFE )

arthritis ⁠treatment ⁠Xeljanz, Eli Lilly's ( LLY ) diabetes drug Trulicity

and AbbVie's ( ABBV ) ‌cosmetic treatment ​Botox.

It is the third round of drugs subject to ⁠the annual ‍price

negotiations ​established under President Joe Biden's signature

Inflation Reduction Act (IRA) of 2022.

For ‍the first time, the list includes the first products

reimbursed under Medicare Part B.

The U.S. Medicare health plan ​said ‍last year that newly

negotiated prices for the 15 drugs ​it negotiated prices for 2027

will save 36% on those medications compared with recent annual

spending, or about $8.5 billion in net covered prescription

costs.